HIV in der Apotheke

HIV in der Pflege

HIV in der Allgemeinmedizin

HIV in der Psychiatrie

HIV in der inneren Medizin

HIV im psychotherapeutischen Setting

HIV in der Intensivmedizin

HIV in der Zahnmedizin

HIV in der Gynäkologie

HIV in der Proktologie

AIDS 2024 – HIV Expert Exchange "Continuum of Care"

AIDS 2024 - HIV Expert Exchange "Person Centric Care"

AIDS 2024 – HIV Expert Exchange "Achieve Equity in Care"

CROI 2024 - Exchange: Aging

CROI 2024 - Exchange: Weight

IAS 2023 - Exchange: Gewichtsveränderung

IAS 2023 - Exchange: Rapid Start

IAS 2023 - Exchange: Resistenzen

Video zum Thema ChemSex

Ein Vortrag von David Stuart

Expertenforum „Persistence“

HIV-Expert*innen beleuchten das Thema „Persistenz“ anhand klinischer Daten und Real-World…

Expertenforum „Forgiveness und Adhärenz“

HIV-Expert*innen beleuchten das Thema „Forgiveness und Adhärenz“ anhand klinischer Daten und…

HIV Perspektivenpapier

Biktarvy Experten Statement 2023

HIV-Expert*innen aus Deutschland, Österreich und der Schweiz beleuchten Real World Studiendaten und…

Sunlenca

Sunlenca 464 mg Injektionslösung

Biktarvy

600 mg/200 mg/245 mg Filmtabletten

Viread

245 mg, 204 mg, 163 mg, 123 mg Filmtabletten und 33 mg/g Granulat

Tybost

150 mg Filmtabletten

Truvada

200 mg/245 mg Filmtabletten

Stribild

150 mg/200 mg/245 mg Filmtabletten

Odefsey

200 mg/25 mg/25 mg Filmtabletten

Genvoya

150 mg/150 mg/200 mg/10 mg Filmtabletten

Eviplera

200 mg/25 mg/245 mg Filmtabletten

Emtriva

200 mg Hartkapseln

Descovy

200 mg/10 mg Filmtabletten und 200 mg/25 mg Filmtabletten

Protopapas, K. et al: Public Awareness towards the U=U Statement A Multi-Country Survey (Austria, Greece and Switzerland)

22.-26.07.2024 / IAS

Miralles, C. et al: Switching to B/F/TAF in a Real-World Cohort of Older People with HIV and a High Burden of Non-AIDS related comorbities

22.-26.07.2024 / IAS

Avihingsanon, A. et al: Factors Associated With HBV Response to B/F/TAF Versus DTG + F/TDF at Week 96 in People With HIV-1 and HBV

03.-06.03.2024 / CROI

Sabranski, M. et al: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Antiretroviral Treatment-Naïve (TN) and -Experienced (TE) People With HIV (PWH): 3-Year Effectiveness and Safety Outcomes in the BICSTaR Observational Cohort.

18.-21.10.2023 / EACS 2023

Esser, S. et al: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced People With HIV (PWH) With Baseline Symptoms of Depression/Anxiety and/or Insomnia in the Observational BICSTaR Study.

18.-21.10.2023 / EACS 2023

Stephan, C. et al: Longer-Term (3-Year) Effectiveness and Safety of B/F/TAF for the Treatment of HIV in the German BICSTaR Cohort

23.-25.03.2023 / DÖAK

Schellberg, S. et al: Three-Year B/F/TAF Use in Treatment-Naive and Treatment-Experienced People Living With HIV in the BICSTaR Cohort Study

23.-25.03.2023 / DÖAK

Ogbuagu, O. et al: Week 52 Subgroup Efficacy of Lenacapavir in Heavily Treatment-Experienced PWH

19.-23.02.2023 / CROI

Avihingsanon, A. et al: Predictors of Hepatitis B treatment response in people with HIV-1/HBV coinfection

19.-22.02.2023 / CROI

Chastek, B. et al: ART Regimen Persistence Among Treatment-Experienced Patients With HIV Switching to a MTR or STR Since 2018

23.-26.10.2022 / HIV Drug Therapy 2022

Castagna. A. et al: Week 52 Subgroup Efficacy Analyses of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People With Multidrug-Resistant HIV (CAPELLA Study)

23.-26.10.2022 / HIV Drug Therapy 2022

Trottier, B. et al: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for the Treatment of People Living With HIV: 24-Month Analyses by Age, Race, Sex, Adherence and Late Diagnosis in a Multi-Country Cohort Study

23.-26.10.2022 / HIV Drug Therapy 2022

Orkin, C. et al: Outcomes After Switching From 144 Weeks of Blinded DTG/ABC/3TC or DTG+F/TAF to 96 Weeks of Open-label B/F/TAF

23.-26.10.2022 / HIV Drug Therapy 2022

Ogbuagu, O. et al: Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People With Multi-Drug Resistant HIV: Week 52 Results

19.-23.10.2022 / ID Week 2022

Ramgopal, M. et al: 5-Year Outcomes of Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial Treatment of HIV-1 in Adults With High Baseline HIV-1 RNA and/or Low CD4 Count in Two Phase 3 Randomized Clinical Trials

23.-26.10.2022 / ID Week 2022

Margot N. et al.: Resistance Analysis of Long-Acting Lenacapavir in Highly Treatment-Experienced People With HIV After 52 Weeks of Treatment

29.07.-02.08.2022 / AIDS 2022

Wohl D. A. et al.: B/F/TAF Five-Year Outcomes in Treatment-Naïve Adults

12.-16.02.2022 / CROI

Ogbuagu O. et al.: Long-Acting Lenacapavir in People With Multidrug-Resistant HIV-1: Week 52 Results

12.-16.02.2022 / CROI

Brunetta J. et al.: Patient-reported outcome (PRO) measures at 12 mo. in a real-world cohort of people living with HIV with a high prevalence of comorbidities receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada and Israel

27.-30.10.2021 / EACS

Mallolas J. et al.: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 12-month effectiveness, persistence, and safety in a multi-country cohort study

27.-30.10.2021 / EACS

Margot, N. et al: Resistance Analysis of Long-Acting Lenacapavir in Highly Treatment-Experienced People with HIV after 26 Weeks of Treatment

27.-30.10.2021 / EACS

Andreatta, K. et al: Long-term Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide After Switch From Boosted Protease Inhibitor-Based Regimens Including in Those With Preexisting Resistance and Viral Blips

27.-30.10.2021 / EACS

Andreatta K. et al.: Prevalence and Risk Factors of Preexisting TAMs in Clinical Trial Participants and Sustained Viral Suppression After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)

27.-30.10.2021 / EACS

Acosta, R. et al: Unreturned Pill Bottles in the 1489 and 1490 Clinical Trials: An Important Measure of Poor Adherence That Is Often Ignored in Pill Count Calculations

29.09.-03.10.2021 / ID Week

Andreatta, K. et al: High Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide in African-American Adults With HIV Including Those with Preexisting Resistance, Viral Blips, and Suboptimal Adherence

29.09.-03.10.2021 / ID Week

Daar, E. et al: Incidence of Metabolic Complications Among Treatment-naïve Adults Living With HIV-1 Randomized to B/F/TAF, DTG/ABC/3TC or DTG + F/TAF After 3 Years

29.09.-03.10.2021 / ID Week

Molina, J.M. et al: Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People with HIV: Week 26 results (CAPELLA study)

18.-21.07.2021 / IAS

Maggiolo, F. et al: Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged 65 years or older: Week 96 results from an international, phase 3b, open-label trial (GS-US-380-4449)

18.-21.07.2021 / IAS

Kumar P. et al.: Week 72 Outcomes and COVID-19 Impact From the BRAAVE 2020 Study: a Randomized Switch to B/F/TAF in Black American Adults With HIV

18.-21.07.2021 / IAS

Arribas, J. et al: Long-term Analysis of B/F/TAF in Treatment-Naïve Adults Living With HIV Through Four Years of Follow-up

18.-21.07.2021 / IAS

Andreatta, K. et al: Long-term Efficacy Among Participants Switched to Bictegravir/Emtricitabine/Tenofovir Alafenamide From Dolutegravir/Abacavir/Lamivudine With Preexisting Resistance and Viral Blips

18.-21.07.2021 / IAS

Acosta R. K. et al.: Achievement of Undetectable HIV-1 RNA in the B/F/TAF Treatment-Naïve Clinical Trials

18.-21.07.2021 / IAS

Natukunda E. et al: B/F/TAF In Virologically Suppressed Adolescents and Children: Two-year Outcomes in 6 to <18 Year Olds and Six-month Outcomes in Toddlers

16.-17.06.2021 / International Workshop on HIV & Pediatrics

Segal-Maurer, S. et al: Potent Antiviral Activity of Lenacapavir in Phase 2/3 in Heavily ART-Experienced PWH

06.-10.03.2021 / CROI 2021